CRISP3 and Its Role in Prostate Cancer with TMPRSS2-ERG Fusion
Author Information
Author(s): Ribeiro Franclim R., Paulo Paula Costa, Vera L. Costa, João D. Barros-Silva, João Ramalho-Carvalho, Carmen Jerónimo, Rui Henrique, Guro E. Lind, Rolf I. Skotheim, Ragnhild A. Lothe, Manuel R. Teixeira
Primary Institution: Portuguese Oncology Institute-Porto, Porto, Portugal
Hypothesis
The study investigates the expression of CRISP3 in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Conclusion
CRISP3 is significantly overexpressed in prostate cancers with the TMPRSS2-ERG fusion gene and is a direct target of the ERG transcription factor.
Supporting Evidence
- CRISP3 showed more than a 50-fold increase in expression in fusion-positive carcinomas compared to fusion-negative ones.
- Immunohistochemistry results indicated CRISP3 protein overexpression in 63% of the carcinomas.
- CRISP3 mRNA levels were strongly correlated with ERG levels (rs=0.65, p<0.001).
- ERG rearrangement was associated with significant expression alterations in genes involved in critical cellular pathways.
Takeaway
This study found that a protein called CRISP3 is much higher in certain prostate cancers, especially those with a specific gene change, which might help doctors understand and treat these cancers better.
Methodology
The study used genome-wide mRNA expression analysis, quantitative real-time PCR, and immunohistochemistry to assess CRISP3 expression in prostate cancer samples.
Potential Biases
Potential biases may arise from the selection of samples and the methods used for gene expression analysis.
Limitations
The study's findings may not be generalizable due to the specific population and sample size.
Participant Demographics
The study involved patients diagnosed with prostate adenocarcinoma, with samples collected from various clinical settings.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website